KU-55933: Potent and Selective ATM Kinase Inhibitor for DNA Damage Response Research

Executive Summary: KU-55933 (APExBIO, A4605) is a nanomolar-potency, highly selective inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, with an IC₅₀ of 13 nM and a K_i of 2.2 nM, favoring ATM over DNA-PK, PI3K/PI4K, ATR, and mTOR targets (APExBIO). It blocks ATM-mediated phosphorylation of Akt at Ser473, reducing cell proliferation and inducing G1 phase cell cycle arrest through cyclin D1 downregulation (Sequiera et al., 2022). KU-55933 demonstrates 50% proliferation inhibition at 10 μM in MDA-MB-453 and PC-3 cancer cell lines and alters cellular metabolism in MCF-7 cells (APExBIO). The compound is widely used for DNA damage response and checkpoint signaling studies, supporting applications in functional genomics and cancer biology (A40926Molecules).

Biological Rationale

ATM kinase is a serine/threonine protein kinase activated in response to DNA double-strand breaks. It orchestrates the DNA damage response (DDR) by phosphorylating substrates that regulate cell cycle checkpoints, apoptosis, and DNA repair (Sequiera et al., 2022). ATM is essential for maintaining genome stability, and its dysfunction is linked to cancer predisposition syndromes such as ataxia-telangiectasia. Inhibition of ATM allows researchers to dissect DDR pathways, study checkpoint signaling, and evaluate synthetic lethality in cancer models. KU-55933 enables selective ATM inhibition, providing high specificity for probe-based mechanistic studies (AKTantibody: further extends the focus on functional genomics; this article details metabolic endpoints and workflow integration).

Mechanism of Action of KU-55933 (ATM Kinase Inhibitor)

KU-55933 is a small molecule that binds the catalytic domain of ATM kinase, preventing ATP from accessing the active site. This competitive inhibition blocks ATM autophosphorylation and downstream phosphorylation of targets, including Akt (Ser473) and other DDR effectors. The selectivity profile shows negligible inhibition of related kinases (DNA-PK, PI3K/PI4K, ATR, mTOR) at concentrations effective for ATM. Inhibition of ATM signaling halts phosphorylation events required for cell cycle progression, notably reducing Akt-mediated survival signaling and leading to G1 cell cycle arrest via cyclin D1 downregulation. In metabolic assays, KU-55933 increases lactate production and glucose consumption while decreasing cellular ATP, indicating a metabolic shift upon ATM blockade (APExBIO product data).

Evidence & Benchmarks

• KU-55933 exhibits an IC₅₀ of 13 nM and a K_i of 2.2 nM for ATM kinase in vitro assays (APExBIO).
• KU-55933 is >100-fold selective for ATM over DNA-PK, PI3K, PI4K, ATR, and mTOR (specificity profiled at 1 μM) (APExBIO).
• 10 μM KU-55933 inhibits proliferation by ~50% in MDA-MB-453 and PC-3 cancer cell lines (cellular proliferation assays) (APExBIO).
• ATM inhibition by KU-55933 blocks phosphorylation of Akt at Ser473, impacting survival and metabolic signaling (Sequiera et al., 2022).
• In MCF-7 cells, KU-55933 increases lactate and glucose uptake and reduces ATP levels, indicating metabolic reprogramming (Sequiera et al., 2022).
• ATM inhibition is pivotal for studies of ataxia-telangiectasia, a genome instability syndrome (Sequiera et al., 2022).

Applications, Limits & Misconceptions

KU-55933 is used extensively to probe ATM function in DDR, cell cycle checkpoints, apoptosis, and metabolic regulation. It is a preferred tool for studying synthetic lethality in cancer models, validating novel DDR targets, and interrogating checkpoint adaptation. The compound is integral in iPSC-based drug screening platforms for personalized medicine in ultrarare disease contexts (Sequiera et al., 2022).

Compared to previous reviews such as Isomaltsyn.com (which emphasizes retrotransposon regulation intersecting ATM signaling), this article provides direct workflow parameters, metabolic endpoints, and clarifies misconceptions regarding selectivity and off-target effects.

Common Pitfalls or Misconceptions

• KU-55933 is not suitable for in vivo applications due to poor water and ethanol solubility.
• Long-term storage of solution stocks at room temperature leads to compound degradation; solutions should be used promptly and kept below -20°C (APExBIO).
• It does not inhibit DNA-PK, PI3K, or ATR at typical working concentrations; lack of effect on these kinases should not be misattributed to ATM inhibition (APExBIO).
• Cellular responses may vary by cell type and baseline DDR pathway integrity; negative results require appropriate controls.
• KU-55933 should not be used as a therapeutic agent; it is for research use only.

Workflow Integration & Parameters

For in vitro studies, KU-55933 is supplied as a solid, soluble at ≥41.67 mg/mL in DMSO with gentle warming (APExBIO). The recommended storage is desiccated at -20°C. Working solutions should be prepared fresh, as long-term DMSO solutions may degrade. Typical working concentrations in cell-based assays are 1–10 μM, with exposure durations ranging from 1 to 48 hours depending on the endpoint (e.g., cell cycle analysis, proliferation, or metabolic shift). For protocol optimization, see KU55933.com, which explores novel cGAS and L1 retrotransposon regulation; this article specifies tested storage, solubility, and metabolic endpoints.

For advanced integrative workflows, KU-55933 is compatible with iPSC-based platforms and functional genomic screens, as highlighted in Sequiera et al., 2022. For further mechanistic and troubleshooting insights, see Hexetidinesyn.com, which offers guidance on ATM inhibition in nuclear cGAS signaling and competitive tool compounds; this article updates the recommended handling and metabolic endpoints.

Conclusion & Outlook

KU-55933 (ATM Kinase Inhibitor) is a gold-standard, potent, and highly selective research tool for dissecting ATM-mediated DNA damage response, cell cycle regulation, and metabolic reprogramming. Its robust selectivity profile, nanomolar potency, and well-characterized benchmarks underpin its widespread adoption in cancer research and functional genomics. As iPSC-based personalized platforms and metabolic profiling expand, KU-55933 will remain essential for mechanistic dissection and translational discovery. For product specifications, protocols, and ordering, see the APExBIO KU-55933 product page.